Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain

Table 1 Murine weights, fasting glycemia levels, glycated haemoglobin levels, and survival numbers in diabetic and non-diabetic mice.

Timepoint	Injection of STZ/Carrier	Month 1	Month 3	Month 5	Month 8
Murine Weight
Non-Diabetic Mice	25.9 +/- 2.8 (n = 25)	33.8 +/- 3.8 (n = 20)	34.7 +/- 3.8 (n = 15)	41.9 +/- 3.9* (n = 10)	46.8 +/- 4.2* (n = 5)
Diabetic Mice	26.1 +/- 3.2 (n = 40)	26.9 +/- 4.2 (n = 33) (2 non-diabetic)	28.4 +/- 4.3 (n = 26)	30.6 +/- 5.7 (n = 18)	31.5 +/- 5.8 (n = 6)
Murine Glycemia and 8 Month HbA1C	Injection of STZ/Carrier	Month 1	Month 3	Month 5	Month 8 (Numbers in brackets indicate glycated haemoglobin levels)
Non-Diabetic Mice	5.4 +/- 2.2	5.7 +/- 2.6	6.0 +/- 2.6	6.1 +/- 3.2	6.4 +/- 3.1* (5.4% +/- 1.8%)
Diabetic Mice	5.5 +/- 2.0	32.1 +/- 5.3	32.5 +/- 5.1	32.4 +/- 5.8	32.6 +/- 5.4 (14.7% +/- 2.1%)^&
Murine Survival Numbers	Injection of STZ/Carrier	Month 1	Month 3	Month 5	Month 8
Non-Diabetic Mice	25/25 (100%)	20/20 (100%)	15/15 (100%)	10/10* (100%)	5/5 (100%)*
Diabetic Mice	40/40 (100%)	33/33 (2 non-diabetic, 100%)	26/30 (87%)	18/25 (72%)	6/20 (30%)

All measures are mean +/- SEM for weights, glycemia levels, and haemoglobin A1C levels. * indicates significance at p < 0.05 with comparison of non-diabetic and diabetic mice cohort groups for weight and glycemic measures (non-matched ANOVA tests, F-values range between 5.68-137.9 for indicated groups and time points, DF ≥ 7,4, n ≥ 5-10 at each time point as indicated. Glycated haemoglobin values are presented in italics in the 8 month column for glycemia levels. Note that 5 diabetic and non-diabetic mice were harvested each month as per protocol) or for survival (Kaplan-Meier Survival statistics, n values indicated).

ISSN: 1744-8069